Stock DNA
Diversified consumer products
INR 36 Cr (Micro Cap)
9.00
34
0.00%
-0.04
24.59%
2.11
Total Returns (Price + Dividend) 
Risk Adjusted Returns v/s 
Returns Beta
News
Is Medistep Health. overvalued or undervalued?
As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen....
Read MoreHow has been the historical performance of Medistep Health.?
Answer: The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability. Breakdown: Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 2...
Read More Announcements 
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Aug 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Prajapati Hetalben Shankarlal (50.08%)
Nitin Singh Bhati (4.69%)
27.29%
Quarterly Results Snapshot (Standalone) - Jun'24 - QoQ
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 23.49% vs 33.65% in Mar 2025
Growth in half year ended Sep 2025 is 20.73% vs 45.56% in Mar 2025
Nine Monthly Results Snapshot (Standalone) - Jun'24
Not Applicable: The company has declared_date for only one period
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 57.02% vs 323.86% in Mar 2024
YoY Growth in year ended Mar 2025 is 42.27% vs 609.76% in Mar 2024






